loader2
Partner With Us NRI

Krsnaa Diagnostics Ltd share Price Today

Company details

645.50
666.00
448.60
767.90
6M Return -9.75%
1Y Return 11.16%
Mkt Cap.(Cr) 2,096.43
Volume 77,355
Div Yield 0.38%
OI
-
OI Chg %
-
Volume 77,355

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Healthcare Services company Krsnaa Diagnostics announced FY24 results:

  • Revenue from Operations: Rs 6,196 million, up 27% YoY
  • EBITDA: Rs 1,461 million, representing an 18% YoY growth with a 24% margin
  • Profit After Tax: Rs 568 million

Commenting on the business, Yash Mutha, Joint Managing Director, said: “I am pleased to announce the outstanding results for the quarter and financial year 2024 which align with our strategic growth plans. Krsnaa Diagnostics is uniquely positioned to capitalize on the burgeoning growth trends in diagnostics Industry.

We are thrilled to announce a historic milestone in India: Krsnaa Diagnostics is the first ever lab operating in a government location to receive the prestigious CAP accreditation, setting a new benchmark for excellence in the industry. The CAP accreditation is a testament to our commitment to quality and excellence in diagnostic services.

We have recently secured a significant agreement with the Maharashtra Government for the installation and operation of 17 MRI and 17 CT machines, which is India’s one of the largest MRI tenders and further cements our leadership in the industry. We are excited to welcome Mr. Mitesh Dave as Group CEO, with him at helm we are poised to accelerate our penetration into the B2C market. We are confident that under Mitesh’s leadership, Krsnaa Diagnostics will continue to set new benchmarks in the diagnostics industry, delivering exceptional value to our stakeholders and enhancing our market position.”

Commenting on the business, Pallavi Bhatevara, Executive Director, said: “Indian Healthcare ecosystem stands to benefit from structural tailwinds like increased consumer awareness, favorable demographics, rise in lifestyle related diseases, and strong thrust towards infrastructure from the public sector. India’s healthcare expenditure - only 3% of GDP has historically remained suppressed vs. global peers owing to higher ‘out of pocket’ expenses and lower health insurance penetration.

Krsnaa Diagnostics continues to play a major role in providing high-quality and affordable diagnostic services. The provision of high-quality and affordable diagnostic services stands as a fundamental pillar within the healthcare industry.

At present, Krsnaa Diagnostics is well-positioned to deploy 67 CT Scan machine, 23 MRI machine, establish 162 labs and set up 3,153 collection centers, all under various contractual agreements. These recent contract wins underscore the exceptional capabilities of our in-house teams, reflecting their proficiency in navigating the intricate bidding process, meeting all necessary requirements, and ultimately securing these contracts. As we embark on these projects, Krsnaa Diagnostics is actively expanding its footprint into new geographical regions, establishing a solid foundation for sustainable, long-term growth.”

Result PDF

View Other Company Results

Krsnaa Diagnostics Ltd shares SWOT Analysis

Strengths (6)

  • Growth in Net Profit with increasing Profit Margin (QoQ)
  • Company with Low Debt
  • Increasing Revenue every Quarter for the past 4 Quarters

Weakness (7)

  • MFs decreased their shareholding last quarter
  • Inefficient use of capital to generate profits - RoCE declining in the last 2 years
  • Inefficient use of shareholder funds - ROE declining in the last 2 years

Opportunity (1)

  • RSI indicating price strength

Threats (1)

  • Red Flag: Resignation of Top Management

Resistance and support

R1 661.7
R2 674.1
R3 682.2
Pivot

653.58

S1 641.2
S2 633.1
S3 620.7
EMA SMA
604.9
601.3
614.9
616.8
593.2
590.9
624.9
650.9
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
KITARA PIIN 1104 Bulk Sell 2024-06-12 600.69 372000 NSE
EAST LANE CAPITAL LLP Block Purchase 2023-10-03 675 150000 NSE
MEDIMAZE SOLUTIONS PRIVATE LIMITED Block Sell 2023-10-03 675 150000 NSE
Name Category Shares
RAJENDRA KHIVRAJ MUTHA PROMOTER 24.87%
KRSNA DIAGNOSTICS (MUMBAI) PRIVATE LIMITED PROMOTER 2.16%

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Krsnaa Diagnostics Ltd Stocks COMPARISON

Financials( in Cr) Krsnaa Diagnostics Ltd Apollo Hospitals Enterprise Ltd Max Healthcare Institute Ltd Fortis Healthcare Ltd Global Health Ltd
Price 649.25 6,236.35 903.05 493.50 1,373.45
% Change -2.57 0.46 -2.68 -1.74 1.27
Mcap Cr 2,096.43 89,669.36 87,768.51 37,257.18 36,878.09
Revenue TTM Cr 487.12 16,612.50 4,831.37 6,537.06 2,694.25
Net Profit TTM Cr 62.11 887.50 1,103.51 632.98 326.08
PE TTM 37.85 99.43 85.36 64.55 76.14
1 Year Return 11.16 24.50 54.79 68.17 109.93
ROCE 11.26 14.16 13.85 7.51 16.49
ROE 8.73 15.04 16.12 6.79 16.13
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 738.74 Cr FV: 5.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 32,550.52 645.34
LAST 3M 105,892.14 -28,833.11
LAST 6M 178,978.26 -15,682.85
LAST 12M 290,242.45 102,068.56
Krsnaa Diagnostics Limited - Analysts/Institutional Investor Meet/Con. Call Updates

Jun 14, 2024 l NSE Announcement

Krsnaa Diagnostics Limited - Analysts/Institutional Investor Meet/Con. Call Updates

Jun 13, 2024 l NSE Announcement

Krsnaa Diagnostics Limited - Analysts/Institutional Investor Meet/Con. Call Updates

Jun 11, 2024 l NSE Announcement

Date Action Type Ratio
Sep 15, 2023 Dividend 55
Sep 15, 2022 Dividend 50

Krsnaa Diagnostics Ltd Information

Stock PE (TTM)
37.85
Promoter Holding
27.03%
Book Value
250.7931
ROCE
11.26%
ROE
8.73%
Description
  • Krsnaa Diagnostics Limited was originally incorporated as `Krsna Diagnostics Private Limited` at Pune, Maharashtra as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated 22 December 2010. The name of the Company was subsequently changed to `Krsnaa Diagnostics Private Limited`, pursuant to a fresh certificate of incorporation issued by the RoC on 29 January 2015. Thereafter, the Company was converted into a public limited company pursuant to a special resolution passed in the extraordinary general meeting of the Shareholders of our Company held on 25 April 2021 and consequently the name of the Company was changed to its present name pursuant to a fresh certificate of incorporation issued by the RoC on 06 May 2021. The company is primarily engaged in providing diagnostic services centres all over India.The company is providing Radiology and Pathology services for X-ray,CT scan,MRI,Mammography,Tele-Reporting services,all type of blood and urine investigation and other related diagnostic services. The company owns an extensive network of integrated diagnostics centres across India primarily in non-metro and lower-tier cities and towns,with operating 1823 diagnostics centres offering radiology and pathology services in 13 states across the country.The company focuses on the public-private partnership(PPP) diagnostics segment and has the largest presence in the diagnostic PPP segment. During the FY2019, the Company has issued 1000 equity shares of face value of Rs. 10/- each at an offer price of Rs. 328.9597 (including Security Premium of Rs. 318.9597/-). The company also issued 30,38,886 Compulsory Convertible Participating Preference Shares [CCPS] of face value of Rs. 250 each at an offer price of Rs. 328.9597 (including Security Premium of Rs. 78.9597). During the FY2021,the company has allotted 730904 equity shares of Rs 10 each through rights issue. Also the company undertook the conversion of 600960 CCPS -Series B into equity shares in the ratio of 1:1 at a price of Rs 250 per share(including the premium of Rs 240 per share). The company,pursuant to a shareholders` resolution dated 25 April 2021,sub-divided the face value of equity shares from Rs 10 to Rs 5 per share. During the month of August 2021,the company came out with Rs 1213.33 crore IPO which comprised a fresh issue of Rs 400 crore and an offer for sale of Rs 813.33 crore by selling shareholders,including PHI Capital Trust,Kitara and Somerset Indus Healthcare Fund.The company will utilise the fresh issue proceeds for establishing diagnostics centres in Punjab,Karnataka,Himachal Pradesh and Maharashtra and also repaying of debts.The allotted shares were listed on the BSE Ltd and National Stock Exchange of India(NSE) on 16 August 2021.

Registered Address

S.No. 243/A Hissa No.6 Near, Chinchwad Station Chinchwad, Pune, Maharashtra, 411019

Tel : 91-20-46954695
Email : cs:krsnadiagnostics.com
Website : http://www.krsnaadiagnostics.com
Registrar

KFin Techologies Ltd

AGM Date (Month) : Jul
Face Value Equity Shares : 5
Market Lot Equity Shares : 1
BSE Code : 543328
NSE Code : KRSNAA
Book Closure Date (Month) : Sep
BSE Group : B
ISIN : INE08LI01020

FAQ’s on Krsnaa Diagnostics Ltd Shares

You can buy Krsnaa Diagnostics Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Krsnaa Diagnostics Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jun 18, 2024 03:56 PM the closing price of Krsnaa Diagnostics Ltd was Rs.649.25.

The latest PE ratio of Krsnaa Diagnostics Ltd as of Jun 18, 2024 03:56 PM is 37.85

The latest PB ratio of Krsnaa Diagnostics Ltd as of Jun 18, 2024 03:56 PM is 0.38

The 52-week high of Krsnaa Diagnostics Ltd share price is Rs. 767.90 while the 52-week low is Rs. 448.60

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Jun 18, 2024 03:56 PM, the market cap of Krsnaa Diagnostics Ltd stood at Rs. 2,096.43.

Download App

Download Our App

Play Store App Store
market app